Skip to main content
Premium Trial:

Request an Annual Quote

VitaGenomics License Affy s Arrays to Develop In Vitro Dx

NEW YORK, Dec. 27 (GenomeWeb News) - Affymetrix granted Vita Genomics non-exclusive access to its microarray technology to develop and market in vitro diagnostics, the companies announced jointly yesterday.

 

Shanghai GeneCore BioTechnologies, a fully owned subsidiary of Vita Genomics, licensed the technology under the "Powered by Affymetrix" program. The program allows companies to license Affymetrix's microarray products such as the GeneChip System 3000Dx.

 

Vita Genomics will develop in vitro tests to detect alpha interferon treatment response in patients with HBV and HCV as well as for early onset and allergic asthma in infants and young children.

 

Vita Genomics will incorporate Affymetrix's arrays into its molecular diagnostic assays.

 

Financial details were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.